Is TB-500 Legal in Texas?

What Is TB-500 and Why Does Its Legal Status Get Complicated?

TB-500 is a synthetic version of thymosin beta-4 (Tβ4), a 43-amino-acid peptide found naturally in nearly all human and animal cells. Researchers have studied it for wound repair, tissue regeneration, and anti-inflammatory effects. The complexity around legality stems from a specific category problem: TB-500 is not a scheduled controlled substance, but it is also not an FDA-approved drug. That two-part reality places it inside a regulatory framework that most patients and even some clinicians find confusing.

The Core Regulatory Problem

The FDA does not automatically prohibit every unapproved substance. Instead, it regulates how substances may be compounded and sold. Compounding pharmacies operate under either Section 503A of the Federal Food, Drug, and Cosmetic Act (for patient-specific prescriptions from traditional pharmacies) or Section 503B (for larger-scale outsourcing facilities). Both pathways restrict which bulk drug substances may be used.

The FDA's bulk drug substances list matters enormously here. If a peptide is not on that list, a 503A pharmacy cannot legally use it to compound a product for a human patient, full stop.

What the FDA Did in 2023

Before 2023, thymosin beta-4 existed in a provisional category allowing limited 503A compounding while the FDA evaluated its clinical legitimacy. In its final guidance published in 2023, the FDA removed thymosin beta-4 from the list of bulk drug substances that may be used by 503A compounders. The FDA's current bulk-drug substances guidance is maintained at the agency's compounding page. This action means a traditional neighborhood compounding pharmacy in Houston, Dallas, or Austin cannot legally fill a TB-500 prescription today.

503B outsourcing facilities operate under a separate, stricter regulatory framework. They must register with the FDA, submit to routine inspections, and follow Current Good Manufacturing Practice (CGMP) standards. The FDA's 503B pathway does not rely on the same nominating list as 503A, which is why some 503B facilities have continued producing thymosin beta-4 under physician-directed protocols. Access to the 503B route is narrower and more expensive, but it is the only remaining federally recognized compounding pathway for this peptide.

Texas State Law: What the TSBP and Medical Practice Act Say

Texas does not have a standalone TB-500 statute. No Texas Penal Code section names thymosin beta-4 specifically. The state's legal framework instead operates through two primary mechanisms: the Texas State Board of Pharmacy (TSBP) and the Texas Medical Practice Act.

Texas State Board of Pharmacy Rules

The TSBP adopts rules that mirror or exceed federal compounding standards. Under Title 22, Texas Administrative Code, Chapter 291, Subchapter F, compounding pharmacies in Texas must comply with federal law on bulk drug substances. Because the FDA removed thymosin beta-4 from the 503A list, Texas 503A pharmacies are now bound by that restriction too. A TSBP-licensed pharmacy that compounds TB-500 under a 503A model after that 2023 FDA action is operating outside federal requirements, which exposes its license to discipline.

Texas does license 503B-equivalent outsourcing facilities separately. Those facilities may ship physician-ordered TB-500 preparations to Texas patients if the product meets CGMP standards and the prescriber has issued a valid prescription following a legitimate patient-physician relationship.

The Texas Medical Practice Act

Under Texas Occupations Code Chapter 151, a physician who prescribes a drug outside its intended use, or prescribes a compounded substance, must do so within the bounds of a legitimate medical practice. That means a documented clinical visit, a verified diagnosis or clinical rationale, informed consent, and ongoing monitoring. Prescribing TB-500 without that framework exposes a physician's license to review by the Texas Medical Board (TMB).

The TMB's rules do not ban experimental or off-label prescribing outright. Off-label prescribing is a long-standing feature of American medicine. The board does, however, require that the practice meet the standard of care for Texas physicians and that the patient be properly informed of the unapproved status of the treatment. A prescriber who orders TB-500 for a patient with a documented musculoskeletal injury, explains the evidence base and its limits, and monitors outcomes is in a different position from one who sells peptide packages over a website with no clinical assessment.

Is Buying TB-500 Online Without a Prescription Legal in Texas?

Short answer: no, not lawfully for human use.

Hundreds of websites sell TB-500 labeled "for research use only" or "not for human consumption." This labeling is a legal hedge that carries real limits. Under 21 U.S.C. § 331, introducing an unapproved new drug into interstate commerce for human use is a federal violation. Texas Health and Safety Code § 431 (the Texas Food, Drug, and Cosmetic Act) mirrors that prohibition at the state level.

The "Research Chemical" Loophole Is Narrower Than It Appears

Vendors selling TB-500 as a research peptide are not selling a controlled substance, so they do not face DEA enforcement. That distinction matters legally. However, if a vendor markets the product with claims about human health benefits, shipping it to a Texas address for personal injection crosses from "gray area" into conduct the FDA has, in prior enforcement letters, characterized as an unlawful sale of an unapproved new drug. The FDA has issued warning letters to peptide vendors citing this exact provision.

The legal exposure falls primarily on vendors, not individual purchasers, in practice. Still, injecting a non-pharmaceutical-grade peptide from an unregulated source carries clinical risks that compound the legal ones. There is no quality assurance, no verified sterility, and no oversight of concentration accuracy in products from unregistered labs.

Anti-Doping Consequences Are Separate From Criminal Law

Athletes subject to WADA or USADA testing face an additional layer of restriction. WADA's 2024 Prohibited List classifies thymosin beta-4 and TB-500 under the peptide hormones, growth factors, related substances, and mimetics category (Section 2). WADA's prohibited list is published annually at wada-ama.org; the underlying pharmacological classification framework is reviewed in published research accessible through PubMed. A Texas-based competitive athlete who uses TB-500 even under a valid physician prescription risks a positive doping test and a sanction, because no Therapeutic Use Exemption (TUE) is available for unapproved peptides under current WADA policy.

The Clinical Evidence Base for TB-500

Understanding the legal status means understanding why physicians bother prescribing it at all. The evidence is early but directional.

Animal and In-Vitro Data

The bulk of TB-500 research comes from animal models. A 2010 study published in the Journal of Molecular and Cellular Cardiology found that thymosin beta-4 administered to mice after myocardial infarction reduced infarct size and improved ventricular function. That study is indexed on PubMed (PMID 20226191). Separate rodent wound-healing studies reported accelerated dermal repair and reduced fibrosis. These findings generated clinical interest but do not constitute human trial evidence.

Human Data: What Exists and What Doesn't

Human clinical trials on TB-500 specifically are sparse. RegeneRx Biopharmaceuticals completed a Phase II trial of thymosin beta-4 eye drops (RGN-259) for dry eye disease, with results showing statistically significant improvements in total ocular symptom scores (P<0.05) compared to placebo in the ARISE-1 and ARISE-2 trials. Trial results are summarized in the NIH clinical trials registry at clinicaltrials.gov and discussed in peer-reviewed analyses on PubMed. That formulation is not the injectable TB-500 most patients seek, but it confirms the peptide does have measurable biological activity in humans at controlled doses.

No large randomized controlled trial has evaluated injectable TB-500 for musculoskeletal injury or systemic recovery in humans. The prescribing rationale used by most physicians is extrapolated from the animal literature and the ocular trial findings, combined with clinical experience.

A Clinical Decision Framework for Texas Physicians

When a Texas physician considers prescribing TB-500 through a compliant 503B pharmacy, the assessment should include at minimum:

1. A documented diagnosis or clinical indication (e.g., tendon injury, post-surgical soft tissue repair).
2. Review of prior treatments tried and failed, to support the off-label rationale.
3. Written informed consent that explicitly states the peptide is not FDA-approved, that human efficacy data are limited, and that the patient understands the legal status.
4. A 503B pharmacy verified to be FDA-registered and operating under CGMP.
5. Scheduled follow-up at 4 and 8 weeks to assess response and document outcomes.

This five-point checklist aligns with the Texas Medical Board's general standard for non-standard treatments and reduces license risk for the prescriber while protecting the patient's interests.

How to Get TB-500 Legally in Texas

Legally obtaining TB-500 in Texas requires three things: a licensed prescriber, a valid prescription following a clinical evaluation, and a 503B-registered compounding pharmacy.

Step 1: Find a Qualified Prescriber

The prescriber must hold an active Texas medical license. In practice, physicians at functional medicine clinics, men's health or women's health telehealth platforms, sports medicine practices, and regenerative medicine offices are most likely to be familiar with TB-500. Telehealth is legal in Texas under Texas Occupations Code § 111.001 et seq., meaning a virtual consultation with a Texas-licensed physician is sufficient to establish the patient-physician relationship required for a lawful prescription. The physician must conduct a history and physical assessment, review labs if clinically indicated, and document a rationale before ordering.

Step 2: Confirm the Pharmacy Is 503B Registered

Before filling a prescription, a patient should verify the pharmacy holds active 503B registration with the FDA. The FDA publishes a publicly searchable list of registered outsourcing facilities. That registry is at accessdata.fda.gov. A pharmacy that claims to compound TB-500 but is not on that list is not operating through a lawful channel.

Step 3: Understand What You Are Receiving

A 503B-compounded TB-500 preparation will typically be supplied as a sterile lyophilized powder in a multi-dose vial, requiring reconstitution with bacteriostatic water before injection. The preparation must include a certificate of analysis from the compounding facility confirming sterility, endotoxin levels, and peptide concentration. Patients should ask for this documentation before injecting. Dosing is physician-directed; common research-referenced ranges are 2 to 5 mg per injection, but no FDA-approved dosing schedule exists.

Federal vs. State: Where the Real Risk Lives

Because TB-500 is not a controlled substance, the DEA plays no role in enforcement for individual users. Federal risk is primarily an issue for vendors and pharmacies that operate outside the compounding framework. State risk in Texas is primarily a licensing issue for physicians and pharmacists who act outside TSBP and TMB rules.

For patients, the clearest risks are clinical rather than criminal: using an unverified peptide from an unregistered source exposes a patient to injection-site infections, systemic contamination, and unknown dosing. The FDA's adverse event reporting database (FAERS) contains reports associated with unregulated peptide injections, though TB-500 specifically is not broken out as a separate category. FAERS data is publicly searchable at fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers.

The legal risk for patients who purchase from gray-market online vendors is low from an enforcement standpoint historically, but that does not make it zero, and FDA enforcement posture toward peptide vendors has tightened since 2021.

Summary of the Regulatory Layers That Govern TB-500 in Texas

| Layer | Authority | Current Status for TB-500 | |---|---|---| | Federal drug approval | FDA (21 U.S.C.) | Not approved; unapproved new drug | | 503A compounding | FDA bulk-drug substances list | Removed from list in 2023; not permitted | | 503B compounding | FDA outsourcing facility registry | Permitted with valid prescription and CGMP compliance | | State pharmacy | Texas State Board of Pharmacy | Must comply with federal compounding rules | | Medical practice | Texas Medical Board | Off-label prescribing permitted with proper documentation | | Controlled substances | DEA / Texas DPS | Not scheduled; no CSA restriction | | Anti-doping | WADA / USADA | Prohibited for competitive athletes |